This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
“The new plant will become the heart of the production operation, while the warehouse and the company’s R&D department will remain at the current site nearby,” says Luigi Pilastro, CEO of CMP Phar.ma. “At both sites, we will work to conceive and produce new inspection machine models to complete the range, to enable us to break into important markets such as North America and China. At the same time, we’ll push ahead with development of our program based on artificial intelligence.”
The aim of the project, which will start to produce the first demos as early as 2024, is to introduce AI as standard on all inspection machines.
“At CMP Phar.ma and within Marchesini Group, we make use of AI algorithms both for the predictive maintenance of our machines and to improve the vision and inspection systems used during packaging cycles, as well as to increase the intelligence of the robotics needed to handle products on our lines,” Maurizio Marchesini, chairman of Marchesini Group explains. “The already impressive results are helping to improve production quality and to release human beings from repetitive tasks and free them up for more ‘human’ jobs.
CMP Phar.ma was one of the first companies to introduce an automatic ampule inspection machine with laser lighting onto the market. Over time, CMP Phar.ma has consolidated its position by creating a product portfolio that includes an extensive range of inspection machines, not only for ampules but also for vials, pre-filled syringes, and freeze-dried products.
Its recent entry into the group of companies controlled by the Marchesini Group - the Bologna-based manufacturer of machines for packaging pharmaceutical and cosmetic industry products - is enabling CMP Phar.ma to contribute its inspection machines to the realization of entire production lines, including those used by Big Pharma for packaging COVID vaccines and cancer drugs, both types of biological drug requiring an extremely high level of quality control.